In experimental pancreatic adenocarcinoma, the combined treatment with mucin-1- (MUC1-)based vaccine and celecoxib, a COX-2 inhibitor, elicited vigorous antitumor responses [88]. Here, MUC1 is linked to pancreatic adenocarcinoma.